Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr 26:4:261-7.
doi: 10.2147/opth.s7971.

Patient persistence with first-line antiglaucomatous monotherapy

Alfonso Arias  1 , Konrad Schargel, Fernando Ussa, Maria I Canut, Amelia Y Belén Robles, Belén Martí Sánchez
Affiliations

Patient persistence with first-line antiglaucomatous monotherapy

Alfonso Arias et al. Clin Ophthalmol. .

Abstract

Purpose: To identify the extent of persistence (period of time of continuous therapy with the drug prescribed) of glaucoma patients treated with prostaglandins (latanoprost, bimatoprost, or travoprost), or beta-blocker (timolol) monotherapy.

Methods: An observational retrospective study of a 24-month follow-up in 191 patients (from four centers) was done to identify the time elapsed until patients discontinued their antiglaucomatous treatment. The relevant information was extracted from patients' medical charts. A descriptive analysis, a Kaplan-Meier survival analysis, and a Cox regression model were used to determine which drug was associated with greater patient persistence and to detect variables significantly influencing persistence.

Results: Descriptive analysis and survival curves showed that after 24 months, latanoprost was associated with a higher persistence in glaucoma treatment than the alternative agents: 81.6% versus 22.9% for bimatoprost, 65.4% for travoprost, and 60.5% for timolol (P < 0.0001). Persistence was significantly influenced by the antiglaucoma agent used as monotherapy (with a six-fold higher risk of treatment discontinuation during the follow-up period due to receiving bimatoprost instead of latanoprost; P < 0.0001) and patient age (P = 0.001). Even though comorbidities could not be directly related to persistence, their occurrence was related to patient age. The main reasons for treatment discontinuation were lack of efficacy, development of intolerance and/or adverse events, which were significant in the bimatoprost group, 28.6% (P < 0.001) and 48.6% (P < 0.001), respectively.

Conclusions: Latanoprost shows higher patient persistence compared with travoprost, bimatoprost, and timolol in routine clinical practice, and could lead to better control of intraocular pressure and lower associated economic costs.

Keywords: Spain; first-line monotherapy; glaucoma; persistence; treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier survival plot (persistence curve).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Foster A, Gilbert C, Johnson G. Changing patterns in global blindness: 1988–2008. Community Eye Health. 2008;21:37–39. - PMC - PubMed
    1. Ferreiro López S, Ruíz Navarro S. Oftalmología en Atención Primaria. Capítulo X: Glaucoma. [Accessed February 10, 2010]. Available at: www.esteve.es/EsteveArchivos/1_8/Ar_1_8_44_APR_9.pdf.
    1. American Academy of Ophthalmology Preferred Practice Patterns Committee Glaucoma Panel. San Francisco: American Academy of Ophthalmology; 2008. [Accessed on 16 March 2010]. Preferred practice pattern: primary open angle glaucoma, limited revision. Available at : one.aao.org/CE/PracticeGuidelines/PPP_Content.aspx?cid.
    1. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7, the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 2000;130:429–440. - PubMed
    1. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–1279. - PubMed